Details of Disease

Disease Name

Late-onset Parkinson disease

Parkinson disease, age of onset, modifier, Multifactorial; late onset Parkinson's disease; hereditary late-onset Parkinson disease; PD; Parkinson disease, susceptibility to, Multifactorial; late onset Parkinson disease; LOPD; autosomal dominant late-onset Parkinson disease; Parkinson disease, late-onset; late-onset Parkinson disease; hereditary late onset Parkinson disease; Parkinson disease, late-onset, susceptibility to, Multifactorial; PARK

Definition

A Parkinson disease that begins after around the age of 50.

Disease Hierarchy

DISQVHKL: Parkinson disease

DIS9IOUI: Late-onset Parkinson disease

Disease Identifiers

MONDO ID

MONDO_0008199

UMLS CUI

C3160718

OMIM ID

168600

MedGen ID

463618

Orphanet ID

411602

General Information of Disease (ID: DIS9IOUI)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 30 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ATXN2	TTPQJ7P	Limited	Genetic Variation	[1]
LAMC2	TTNS7H3	Limited	Altered Expression	[2]
TPO	TT52XDZ	Limited	Genetic Variation	[3]
LRRK2	TTK0FEA	moderate	Biomarker	[4]
ATXN3	TT6A17J	Strong	Biomarker	[1]
C9orf72	TTA4SHR	Strong	Genetic Variation	[5]
CA12	TTSYM0R	Strong	Altered Expression	[6]
CHM	TTOA18V	Strong	Genetic Variation	[7]
CYP2D6	TTVG215	Strong	Genetic Variation	[8]
DRD3	TT4C8EA	Strong	Genetic Variation	[9]
DRD5	TTS2PH3	Strong	Genetic Variation	[10]
GALC	TT5IZRB	Strong	Genetic Variation	[11]
GBA	TT1B5PU	Strong	Genetic Variation	[12]
GBA1	TTCYHJ4	Strong	Autosomal dominant	[13]
GLA	TTIS03D	Strong	Genetic Variation	[14]
HTR2A	TTJQOD7	Strong	Genetic Variation	[9]
LINGO1	TTZYQ80	Strong	Altered Expression	[15]
MAPT	TTXZCO0	Strong	Autosomal dominant	[13]
MAPT	TTS87KH	Strong	Biomarker	[16]
MSMB	TTYH1ZK	Strong	Biomarker	[17]
P2RY6	TTNVSKA	Strong	Biomarker	[18]
SETD7	TTJ0FSU	Strong	Altered Expression	[19]
SF3B1	TTL2WUI	Strong	Biomarker	[20]
SGCA	TTS9Q5V	Strong	Genetic Variation	[21]
SMPD1	TTJTM88	Strong	Genetic Variation	[22]
SOST	TTYRO4F	Strong	Biomarker	[23]
SPTBN1	TTS9BDA	Strong	Genetic Variation	[24]
TARDBP	TT9RZ03	Strong	Genetic Variation	[25]
TPH2	TT3KLDP	Strong	Genetic Variation	[26]
NR4A2	TT9HKN3	Definitive	Altered Expression	[27]
------------------------------------------------------------------------------------


⏷ Show the Full List of 30 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC41A1	DTB37ZE	Strong	Genetic Variation	[28]
------------------------------------------------------------------------------------

This Disease Is Related to 53 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSBG1	OTM040MW	Strong	Biomarker	[29]
ANO3	OTM34U6Q	Strong	Genetic Variation	[30]
APOD	OTT77XW8	Strong	Biomarker	[31]
ASXL1	OTX931AW	Strong	Biomarker	[20]
B3GALT4	OTLKSMQE	Strong	Altered Expression	[32]
BPIFA2	OTLFSDZD	Strong	Biomarker	[17]
C19orf12	OTVSJ1AR	Strong	Biomarker	[5]
C1QC	OTLE5U1P	Strong	Biomarker	[33]
CARTPT	OTTE4V9S	Strong	Genetic Variation	[34]
CDAN1	OTCVZRG6	Strong	Biomarker	[35]
CHCHD2	OTL5PA3Y	Strong	Genetic Variation	[36]
CLEC4D	OTT7X1UC	Strong	Biomarker	[37]
CNDP1	OTOYSQG7	Strong	Genetic Variation	[38]
CYP20A1	OTIUZ6CF	Strong	Genetic Variation	[39]
DNAJC13	OTYAVVJ6	Strong	Genetic Variation	[40]
EEF1A2	OT9Z23K5	Strong	Biomarker	[41]
ELAVL4	OT3YH6J6	Strong	Genetic Variation	[42]
GBA1	OT0XMD63	Strong	Autosomal dominant	[13]
GIGYF2	OTFNVEJ4	Strong	Genetic Variation	[43]
GLIS1	OTBDNB26	Strong	Genetic Variation	[44]
HERPUD1	OT9EROL6	Strong	Altered Expression	[45]
HTRA2	OTC7616F	Strong	Genetic Variation	[46]
ITSN2	OT8S0OO8	Strong	Genetic Variation	[47]
LRRK1	OTCQMOIX	Strong	Genetic Variation	[48]
LY6E	OTMG16BZ	Strong	Biomarker	[1]
MAPT	OTMTP2Z7	Strong	Autosomal dominant	[13]
MARCHF7	OTG9SF10	Strong	Biomarker	[49]
NFAT5	OTKIE59S	Strong	Altered Expression	[50]
NTM	OTHF0UQU	Strong	Biomarker	[51]
PAFAH1B1	OT9T2TCJ	Strong	Biomarker	[20]
PINK1	OT50NR57	Strong	Genetic Variation	[52]
PLEKHO1	OTMVUQ9W	Strong	Altered Expression	[53]
PRPH2	OTNH2G5H	Strong	Genetic Variation	[54]
PRRX2	OT8UR4AU	Strong	Biomarker	[55]
PSPH	OTV1PVAX	Strong	Biomarker	[17]
PSPN	OT54LLZJ	Strong	Biomarker	[17]
RAD23A	OTBPAWHX	Strong	Biomarker	[56]
RAPH1	OTMQXW7S	Strong	Biomarker	[29]
RHOT1	OTBIRR8Q	Strong	Biomarker	[57]
RIDA	OTW4098I	Strong	Biomarker	[17]
ROM1	OTE7H0YV	Strong	Biomarker	[58]
SARM1	OTEP4I5O	Strong	Altered Expression	[59]
SFSWAP	OT7H3ETA	Strong	Genetic Variation	[47]
SKP1	OT5BPAZ4	Strong	Biomarker	[60]
ST3GAL2	OT8WM21E	Strong	Altered Expression	[32]
STH	OTK8ULTH	Strong	Genetic Variation	[61]
STXBP3	OTTTYMAQ	Strong	Biomarker	[17]
TMEM132E	OTHCX3RI	Strong	Biomarker	[62]
TMEM230	OTAFALFV	Strong	Biomarker	[63]
TMEM98	OTKDUEED	Strong	Biomarker	[62]
TOMM40	OTZDQ29F	Strong	Genetic Variation	[64]
TRAP1	OTNG0L8J	Strong	Genetic Variation	[65]
TRAT1	OTMPUNPD	Strong	Genetic Variation	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 53 DOT(s)

References

1	Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: genetic, clinical, and positron emission tomography findings.Mov Disord. 2009 Oct 15;24(13):2007-11. doi: 10.1002/mds.22727.
2	CSF or serum neurofilament light added to -Synuclein panel discriminates Parkinson's from controls.Mov Disord. 2020 Feb;35(2):288-295. doi: 10.1002/mds.27897. Epub 2019 Nov 18.
3	Factors associated with deterioration of health-related quality of life in multiple system atrophy: 1-year follow-up study.Acta Neurol Belg. 2018 Dec;118(4):589-595. doi: 10.1007/s13760-018-0962-4. Epub 2018 Jun 11.
4	Caught in the act: LRRK2 in exosomes.Biochem Soc Trans. 2019 Apr 30;47(2):663-670. doi: 10.1042/BST20180467. Epub 2019 Mar 5.
5	Mutations in C19orf12 and intronic repeat expansions in C9orf72 not observed in Iranian Parkinson's disease patients.Neurobiol Aging. 2017 Jun;54:214.e11-214.e12. doi: 10.1016/j.neurobiolaging.2017.03.020. Epub 2017 Mar 18.
6	Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome.Radiat Oncol. 2010 Nov 1;5:101. doi: 10.1186/1748-717X-5-101.
7	SNCA Rep1 promoter variability influences cognition in Parkinson's disease.Mov Disord. 2019 Aug;34(8):1232-1236. doi: 10.1002/mds.27768. Epub 2019 Jun 24.
8	Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands.Pharmacogenet Genomics. 2008 Mar;18(3):209-12. doi: 10.1097/FPC.0b013e3282f5106e.
9	Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.Parkinsonism Relat Disord. 2016 Sep;30:13-7. doi: 10.1016/j.parkreldis.2016.06.005. Epub 2016 Jun 15.
10	Expression of Dopamine Receptors in Immune Regulatory Cells.Neuroimmunomodulation. 2019;26(3):159-166. doi: 10.1159/000501187. Epub 2019 Jul 16.
11	Analysis of age-related changes in psychosine metabolism in the human brain.PLoS One. 2018 Feb 26;13(2):e0193438. doi: 10.1371/journal.pone.0193438. eCollection 2018.
12	Deep brain stimulation for monogenic Parkinson's disease: a systematic review.J Neurol. 2020 Apr;267(4):883-897. doi: 10.1007/s00415-019-09181-8. Epub 2019 Jan 18.
13	The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
14	Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees.J Parkinsons Dis. 2020;10(1):141-152. doi: 10.3233/JPD-191704.
15	Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14430-5. doi: 10.1073/pnas.0700901104. Epub 2007 Aug 28.
16	Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.Mov Disord. 2018 Mar;33(3):431-439. doi: 10.1002/mds.27284. Epub 2018 Feb 13.
17	Manual MRI morphometry in Parkinsonian syndromes.Mov Disord. 2017 May;32(5):778-782. doi: 10.1002/mds.26921. Epub 2017 Feb 2.
18	Microglia P2Y6 receptor is related to Parkinson's disease through neuroinflammatory process.J Neuroinflammation. 2017 Feb 20;14(1):38. doi: 10.1186/s12974-017-0795-8.
19	Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis.PLoS One. 2018 May 3;13(5):e0196844. doi: 10.1371/journal.pone.0196844. eCollection 2018.
20	Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?.Parkinsonism Relat Disord. 2019 Jul;64:242-248. doi: 10.1016/j.parkreldis.2019.04.018. Epub 2019 Apr 28.
21	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.Parkinsonism Relat Disord. 2017 Jun;39:37-43. doi: 10.1016/j.parkreldis.2017.02.007. Epub 2017 Feb 7.
22	SMPD1 mutations, activity, and -synuclein accumulation in Parkinson's disease.Mov Disord. 2019 Apr;34(4):526-535. doi: 10.1002/mds.27642. Epub 2019 Feb 20.
23	Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study.BMC Nephrol. 2019 Jul 17;20(1):266. doi: 10.1186/s12882-019-1452-5.
24	50-Hz MF does not affect global DNA methylation of SH-SY5Y cells treated with the neurotoxin MPP().Bioelectromagnetics. 2019 Jan;40(1):33-41. doi: 10.1002/bem.22158. Epub 2018 Dec 7.
25	Mutational analysis of TARDBP gene in patients affected by Parkinson's disease from Calabria.J Neurol Sci. 2018 Jul 15;390:209-211. doi: 10.1016/j.jns.2018.04.043. Epub 2018 May 1.
26	Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder.Neurosci Lett. 2007 Jan 16;411(3):180-4. doi: 10.1016/j.neulet.2006.09.060. Epub 2006 Nov 22.
27	Identification of NURR1 (Exon 4) and FOXA1 (Exon 3) Haplotypes Associated with mRNA Expression Levels in Peripheral Blood Lymphocytes of Parkinson's Patients in Small Indian Population.Parkinsons Dis. 2017;2017:6025358. doi: 10.1155/2017/6025358. Epub 2017 Jan 31.
28	Genetic variants in the RAB7L1 and SLC41A1 genes of the PARK16 locus in Chinese Parkinson's disease patients.Int J Neurosci. 2011 Nov;121(11):632-6. doi: 10.3109/00207454.2011.598983. Epub 2011 Aug 4.
29	Clinical characteristics and quality of life in Chinese patients with Parkinson's disease beyond 20years.Neurol Res. 2018 Apr;40(4):312-317. doi: 10.1080/01616412.2018.1438227. Epub 2018 Feb 15.
30	Role of ANO3 mutations in dystonia: A large-scale mutational screening study.Parkinsonism Relat Disord. 2019 May;62:196-200. doi: 10.1016/j.parkreldis.2018.12.030. Epub 2019 Jan 2.
31	Apolipoprotein D Concentration in Human Plasma during Aging and in Parkinson's Disease: A Cross-Sectional Study.Parkinsons Dis. 2018 Mar 26;2018:3751516. doi: 10.1155/2018/3751516. eCollection 2018.
32	siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration.Mol Cell Neurosci. 2019 Mar;95:25-30. doi: 10.1016/j.mcn.2019.01.001. Epub 2019 Jan 3.
33	Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease.Neurosci Lett. 2015 May 6;594:66-9. doi: 10.1016/j.neulet.2015.03.048. Epub 2015 Mar 26.
34	Hypothalamic Energy Regulatory Peptides in Chronic Kidney Disease.Ther Apher Dial. 2019 Oct;23(5):437-443. doi: 10.1111/1744-9987.12798. Epub 2019 Mar 21.
35	Musculoskeletal ultrasound as a biomarker of remission - results from a one-year prospective study in patients with rheumatoid arthritis.Med Ultrason. 2018 Dec 8;20(4):453-460. doi: 10.11152/mu-1609.
36	Varied pathological and therapeutic response effects associated with CHCHD2 mutant and risk variants.Hum Mutat. 2017 Aug;38(8):978-987. doi: 10.1002/humu.23234. Epub 2017 May 22.
37	New Dopamine D2 Receptor Agonist, [(3)H]MCL-536, for Detecting Dopamine D2high Receptors in Vivo.ACS Chem Neurosci. 2018 Jun 20;9(6):1283-1289. doi: 10.1021/acschemneuro.8b00096. Epub 2018 Apr 16.
38	Relationship between carnosinase gene CNDP1 leucine repeat polymorphism and the clinical outcome of Chinese PD patients.Clin Nephrol. 2010 Nov;74(5):343-5. doi: 10.5414/cnp74343.
39	Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease.Ann Neurol. 1996 Sep;40(3):463-5. doi: 10.1002/ana.410400319.
40	DNAJC13 genetic variants in parkinsonism.Mov Disord. 2015 Feb;30(2):273-8. doi: 10.1002/mds.26064. Epub 2014 Nov 12.
41	Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.Mov Disord. 2020 Feb;35(2):337-343. doi: 10.1002/mds.27910. Epub 2019 Nov 23.
42	ELAVL4, PARK10, and the Celts.Mov Disord. 2007 Mar 15;22(4):585-7. doi: 10.1002/mds.21336.
43	GIGYF2 mutation in late-onset Parkinson's disease with cognitive impairment.J Hum Genet. 2015 Oct;60(10):637-40. doi: 10.1038/jhg.2015.69. Epub 2015 Jul 2.
44	GLIS1 rs797906: an increased risk factor for late-onset Parkinson's disease in the Han Chinese population.Eur Neurol. 2012;68(2):89-92. doi: 10.1159/000337955. Epub 2012 Jul 3.
45	Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies.Clin Neuropathol. 2009 Sep-Oct;28(5):333-43.
46	Mitochondrial defects and neurodegeneration in mice overexpressing wild-type or G399S mutant HtrA2.Hum Mol Genet. 2016 Feb 1;25(3):459-71. doi: 10.1093/hmg/ddv485. Epub 2015 Nov 24.
47	Personality and Personality Disorders in Medication-Overuse Headache: A Controlled Study by SWAP-200.Pain Res Manag. 2019 Jun 12;2019:1874078. doi: 10.1155/2019/1874078. eCollection 2019.
48	Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway.Neurosci Lett. 2007 Apr 18;416(3):299-301. doi: 10.1016/j.neulet.2007.02.020. Epub 2007 Feb 12.
49	Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies.Front Neurol. 2018 Dec 4;9:1018. doi: 10.3389/fneur.2018.01018. eCollection 2018.
50	Activation of nuclear factor of activated T cells 5 in the peritoneal membrane of uremic patients.Am J Physiol Renal Physiol. 2015 Jun 1;308(11):F1247-58. doi: 10.1152/ajprenal.00617.2014. Epub 2015 Apr 1.
51	Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.BMC Pharmacol Toxicol. 2019 Jun 3;20(1):37. doi: 10.1186/s40360-019-0302-1.
52	Mutation analysis of the PINK1 gene in Southern Italian patients with early- and late-onset parkinsonism.Parkinsonism Relat Disord. 2012 Jun;18(5):651-3. doi: 10.1016/j.parkreldis.2011.08.017. Epub 2011 Sep 17.
53	Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating CKIP-1 to resist HG-induced up-regulation of FN and ICAM-1 in GMCs and diabetic mice kidneys.Free Radic Biol Med. 2017 May;106:393-405. doi: 10.1016/j.freeradbiomed.2017.03.003. Epub 2017 Mar 10.
54	Autosomal Dominant Retinal Dystrophies Caused by a Founder Splice Site Mutation, c.828+3A>T, in PRPH2 and Protein Haplotypes in trans as Modifiers.Invest Ophthalmol Vis Sci. 2016 Feb;57(2):349-59. doi: 10.1167/iovs.15-16965.
55	Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.J Neurosci. 2011 Jan 5;31(1):247-61. doi: 10.1523/JNEUROSCI.4589-10.2011.
56	The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair.Neurobiol Dis. 2006 Sep;23(3):708-16. doi: 10.1016/j.nbd.2006.06.005. Epub 2006 Jul 24.
57	Lysine 27 ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of the Parkin ubiquitin ligase.J Biol Chem. 2014 May 23;289(21):14569-82. doi: 10.1074/jbc.M114.563031. Epub 2014 Mar 26.
58	Rom1 converts Y141C-Prph2-associated pattern dystrophy to retinitis pigmentosa.Hum Mol Genet. 2017 Feb 1;26(3):509-518. doi: 10.1093/hmg/ddw408.
59	c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD(+) cleavage activity to inhibit mitochondrial respiration.J Biol Chem. 2018 Dec 7;293(49):18933-18943. doi: 10.1074/jbc.RA118.004578. Epub 2018 Oct 17.
60	Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease.Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S177-9. doi: 10.1016/S1353-8020(11)70055-4.
61	Association of rs62063857 variant of the saitohin gene with Parkinson's disease.Cell Mol Neurobiol. 2015 Jan;35(1):115-21. doi: 10.1007/s10571-014-0102-5. Epub 2014 Aug 29.
62	Are TMEM genes potential candidate genes for panic disorder?.Psychiatr Genet. 2014 Feb;24(1):37-41. doi: 10.1097/YPG.0000000000000022.
63	TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?.Mov Disord. 2017 Aug;32(8):1159-1162. doi: 10.1002/mds.27061. Epub 2017 Jun 1.
64	A candidate gene study of risk for dementia in older, postmenopausal women: Results from the Women's Health Initiative Memory Study.Int J Geriatr Psychiatry. 2019 May;34(5):692-699. doi: 10.1002/gps.5068. Epub 2019 Mar 7.
65	Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.Brain. 2017 Sep 1;140(9):2444-2459. doi: 10.1093/brain/awx202.
66	The Transcriptional Changes of trim Genes Associated with Parkinson's Disease on a Model of Human Induced Pluripotent Stem Cells.Mol Neurobiol. 2017 Nov;54(9):7204-7211. doi: 10.1007/s12035-016-0230-7. Epub 2016 Oct 29.